Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.68 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.47 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | CASP2 | P42575 | 1/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17180570 | 0.87 | GLP1R (0.75) | GLP1RNOD1LPAR3LPAR1NAAA | |
| SCHEMBL15259274 | 0.87 | GLP1R (0.75) | GLP1RNOD1LPAR3LPAR1TLR2 | |
| SCHEMBL14438807 | 0.87 | GLP1R (0.75) | GLP1RNOD1LPAR3LPAR1NAAA | |
| SCHEMBL17180569 | 0.87 | GLP1R (0.75) | GLP1RNOD1LPAR3LPAR1TLR2 | |
| SCHEMBL22648047 | 0.87 | GLP1R (0.77) | GLP1RNOD1EPHX2 | |
| SCHEMBL16656538 | 0.86 | GLP1R (0.76) | GLP1RNOD1EPHX2 | |
| SCHEMBL17189428 | 0.86 | GLP1R (0.70) | GLP1RNOD1LPAR3LPAR1TLR2 | |
| SCHEMBL14438806 | 0.86 | GLP1R (0.70) | GLP1RNOD1LPAR3LPAR1TLR2 | |
| SCHEMBL15259287 | 0.86 | GLP1R (0.70) | GLP1RNOD1LPAR3LPAR1TLR2 | |
| SCHEMBL25912500 | 0.86 | GLP1R (0.72) | GLP1RNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200306379-A1 | INJECTABLE PH 7 SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN HAVING A PI FROM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS | ADOCIA (FR) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200306379-A1 | INJECTABLE PH 7 SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN HAVING A PI FROM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS | IAPP, INSR, IGFBP5 | GLP1R 31/4885NOD1 1960/4885FAAH 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.